ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -47 مورد

Tigecycline: Pediatric drug information

Tigecycline: Pediatric drug information
2025© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Tigecycline: Drug information" and "Tigecycline: Patient drug information"

For abbreviations, symbols, and age group definitions show table
ALERT: US Boxed Warning
Mortality:

An increase in all-cause mortality has been observed in a meta-analysis of phase 3 and 4 clinical trials in tigecycline-treated patients versus comparator. The cause of this mortality risk difference of 0.6% (95% confidence interval [CI], 0.1 to 1.2) has not been established. Tigecycline should be reserved for use in situations when alternative treatments are not suitable.

Brand Names: US
  • Tygacil
Brand Names: Canada
  • Tygacil
Therapeutic Category
  • Antibiotic, Glycylcycline
Dosing: Pediatric

General dosing, bacterial infection: Limited data available: Note: Use should be reserved for situations when no effective alternative therapy is available and when benefits are expected to outweigh risks (Ref). Duration of therapy dependent on severity and site of infection and response to therapy.

Infants and Children <8 years: Reported dosing variable: Note: Use in in patients <8 years is not recommended due to adverse effects on tooth development and uncertain dosing; however, use has been described in scenarios where alternative options were unavailable (Ref).

IV: 1.5 to 2 mg/kg loading dose once, then 1 to 2 mg/kg/dose every 12 hours; maximum dose: 50 mg/dose (Ref). Note: Higher loading doses of up to 4 mg/kg/dose have also been reported to treat multidrug resistant gram-negative bacteria (Ref).

Children ≥8 years and Adolescents: IV: 1.5 to 2 mg/kg loading dose once, then 1.2 to 2 mg/kg/dose every 12 hours; usual maximum dose: 50 mg/dose (Ref). A higher dose (4 mg/kg loading dose [maximum dose: 200 mg/dose], followed by 2 to 3.2 mg/kg/dose [maximum dose: 100 mg/dose] every 12 hours) has been suggested to mimic high-dose therapy used in adults, particularly for infections caused by carbapenem-resistant Enterobacterales infections (Ref).

Mycobacterial infection, nontuberculous; pulmonary

Mycobacterial infection, nontuberculous; pulmonary: Limited data available: Note: Use as part of an appropriate combination regimen; typically treat ≥12 months after culture conversion (Ref).

Children 8 to <12 years: IV: 1.2 mg/kg/dose every 12 hours; maximum dose: 50 mg/dose (Ref).

Children ≥12 years and Adolescents: IV: 100 mg loading dose once, followed by 50 mg every 12 to 24 hours (Ref). Note: A reduced dosage regimen of 50 mg every 24 hours or 25 mg every 12 to 24 hours may be considered in patients who do not tolerate higher doses (Ref).

Dosing: Kidney Impairment: Pediatric

Altered kidney function: There are no pediatric-specific recommendations provided in the manufacturer's labeling; based on experience in adult patients, no dosage adjustment necessary.

Hemodialysis: Poorly dialyzed. There are no pediatric-specific recommendations provided in the manufacturer's labeling; based on experience in adult patients, no dosage adjustment necessary.

Dosing: Liver Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling. In adult patients with mild to moderate impairment (Child-Pugh class A or B), no dosage adjustment necessary; for severe hepatic impairment (Child Pugh class C), dosing adjustment is suggested.

Dosing: Adult

(For additional information see "Tigecycline: Drug information")

Note: Given the increased mortality risk associated with tigecycline, reserve for use in situations when alternative treatments are not suitable (Ref).

Acinetobacter baumannii infection, multidrug resistant

Acinetobacter baumannii infection, multidrug resistant (alternative agent) (off-label use): IV: 200 mg once, then 100 mg every 12 hours as part of an appropriate combination regimen (Ref).

Intra-abdominal infection

Intra-abdominal infection (alternative agent):

Note: Not recommended for routine empiric use. Reserve use for patients with or at risk for certain multidrug-resistant organisms (eg, K. pneumoniae carbapenemase-producing Enterobacteriaceae, Acinetobacter baumannii) (Ref).

IV: 100 mg once, then 50 mg every 12 hours (Ref); some experts suggest 200 mg once, then 100 mg every 12 hours for resistant infection (Ref). Some experts use as part of an appropriate combination regimen for certain resistant organisms (Ref). Total duration of therapy (which may include transition to oral antibiotics) is 4 to 5 days following adequate source control (Ref).

Mycobacterial infection

Mycobacterial (nontuberculous, rapidly growing) infection (off-label use):

Note: Patients should be under the care of a clinician with expertise in managing mycobacterial infection (Ref).

IV: 25 to 50 mg once or twice daily as part of an appropriate combination regimen (Ref). Some experts administer 100 mg once as a loading dose (Ref).

Pneumonia, community acquired

Pneumonia, community acquired (alternative agent for patients unable to tolerate beta-lactams or fluoroquinolones): Inpatients without risk factors for Pseudomonas aeruginosa; not recommended for routine empiric use (Ref).

IV: 100 mg as a single dose, then 50 mg every 12 hours (Ref). Total duration (which may include oral step-down therapy) is a minimum of 5 days; patients should be clinically stable with normal vital signs before therapy is discontinued (Ref).

Skin/skin structure infection, complicated

Skin/skin structure infection, complicated: IV: Initial: 100 mg as a single dose; Maintenance dose: 50 mg every 12 hours for 5 to 14 days.

Stenotrophomonas maltophilia infection, multidrug resistant

Stenotrophomonas maltophilia infection, multidrug resistant (alternative agent) (off-label use): IV: 200 mg once, then 100 mg every 12 hours as part of an appropriate combination regimen (Ref).

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Altered kidney function: No dosage adjustment necessary for any degree of kidney dysfunction (Ref).

Hemodialysis, intermittent (thrice weekly): Poorly dialyzed: No supplemental dose or dosage adjustment necessary (Ref).

Peritoneal dialysis: Unlikely to be dialyzed: No dosage adjustment necessary (Ref).

CRRT: No dosage adjustment necessary (Ref).

PIRRT (eg, sustained, low-efficiency diafiltration): No dosage adjustment necessary (Ref).

Dosing: Liver Impairment: Adult

Mild-to-moderate hepatic impairment (Child-Pugh class A or B): No dosage adjustment necessary.

Severe hepatic impairment (Child-Pugh class C): Initial: 100 mg single dose; Maintenance: 25 mg every 12 hours.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

>10%: Gastrointestinal: Diarrhea (12%), nausea (24% to 35%), vomiting (16% to 20%)

1% to 10%:

Cardiovascular: Phlebitis (3%), septic shock, thrombophlebitis

Dermatologic: Pruritus, skin rash (3%)

Endocrine & metabolic: Hypocalcemia, hypoglycemia, hyponatremia (2%), increased amylase (3%)

Gastrointestinal: Abdominal pain (6%), abnormal stools, anorexia, dysgeusia, dyspepsia (2%)

Genitourinary: Leukorrhea, vaginitis, vulvovaginal candidiasis

Hematologic & oncologic: Anemia (5%), eosinophilia, hypoproteinemia (5%), increased INR, prolonged partial thromboplastin time, prolonged prothrombin time, thrombocytopenia

Hepatic: Hyperbilirubinemia (2%), increased serum alanine aminotransferase (5%), increased serum alkaline phosphatase (3%), increased serum aspartate aminotransferase (4%), jaundice

Hypersensitivity: Hypersensitivity reaction

Infection: Abscess (2%), infection (7%), sepsis

Local: Inflammation at injection site, injection site phlebitis, injection site reaction, pain at injection site, swelling at injection site

Nervous system: Chills, dizziness (3%), headache (6%)

Neuromuscular & skeletal: Asthenia (3%)

Renal: Increased blood urea nitrogen (3%), increased serum creatinine

Respiratory: Pneumonia (2%)

Postmarketing:

Dermatologic: Severe dermatological reaction, Stevens-Johnson syndrome

Gastrointestinal: Acute pancreatitis, Clostridioides difficile associated diarrhea, enamel hypoplasia

Hematologic & oncologic: Hemorrhage (including rectal bleeding and ecchymoses [Ciu 2019]), hypofibrinogenemia

Hepatic: Hepatic failure, intrahepatic cholestasis

Hypersensitivity: Anaphylaxis, nonimmune anaphylaxis

Contraindications

Hypersensitivity (eg, anaphylaxis) to tigecycline or any component of the formulation.

Canadian labeling: Additional contraindications (not in US labeling): Hypersensitivity to tetracycline class of antibiotics.

Warnings/Precautions

Concerns related to adverse effects:

• Anaphylactic/Hypersensitivity reactions: May cause life-threatening anaphylaxis. Due to structural similarity with tetracyclines, avoid use in patients with known hypersensitivity to tetracycline-class antibiotics.

• Antianabolic effects: May be associated with antianabolic effects observed with the tetracycline class (including increased BUN, azotemia, acidosis, and hyperphosphatemia). Discontinue use if antianabolic effects occur.

• Coagulopathy: May be associated with abnormalities of blood coagulation parameters, including prolongation of PT and aPTT and decreased fibrinogen that may be dose- and/or time-dependent, in particular in patients with renal and hepatic impairment; discontinue use when suspected (Cui 2019).

• Fixed drug eruption: May be associated with fixed drug eruption due to structural similarities with tetracyclines. Discontinue use if fixed drug reaction is suspected.

• Hepatotoxicity: Abnormal liver function tests (increased total bilirubin, prothrombin time, transaminases) have been reported. Isolated cases of significant hepatic dysfunction and hepatic failure have occurred. Adverse hepatic effects may occur after drug discontinuation.

• Pancreatitis: Acute pancreatitis (including fatalities) has been reported, including patients without known risk factors; discontinue use when suspected.

• Photosensitivity: May be associated with photosensitivity due to structural similarities with tetracyclines. Discontinue use if photosensitivity occurs.

• Pseudotumor cerebri: May be associated with pseudotumor cerebri due to structural similarities with tetracyclines. Discontinue use if pseudotumor cerebri occurs.

• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed >2 months postantibiotic treatment.

• Treatment-related mortality: In general, deaths were the result of worsening infection, complications of infection, or underlying comorbidity.

Disease-related concerns:

• Hepatic impairment: Use with caution in patients with hepatic impairment; dosage adjustment recommended in severe hepatic impairment.

• Intra-abdominal infections: Avoid use as monotherapy for patients with intestinal perforation (in the small sample of available cases, sepsis/septic shock occurred more frequently than patients treated with imipenem/cilastatin comparator).

Special populations:

• Pediatric: Safety and efficacy in children and adolescents <18 years of age have not been established due to increased mortality observed in trials of adult patients. Use only if no alternative antibiotics are available. Because of potential effects on tooth development (yellow-gray-brown discoloration), use in patients <8 years of age is not recommended.

Other warnings/precautions:

• Appropriate use: Do not use for diabetic foot infections; non-inferiority was not demonstrated in studies. Do not use for healthcare-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP); increased mortality and decreased efficacy have been reported in HAP and VAP trials.

Warnings: Additional Pediatric Considerations

Tigecycline use in individuals <8 years of age may result in permanent tooth discoloration (yellow, gray, or brown) and/or enamel hypoplasia. Specific incidence of tooth discoloration following tigecycline treatment in patients <8 years is unknown; with tetracyclines in general, discoloration is more common with long-term use but may also be observed with repeated, short courses. While doxycycline courses up to 21 days have been considered acceptable and low-risk for discoloration, doxycyclines calcium-binding capacity is lower than that of tetracycline; tigecyclines calcium-binding capacity is not known (Red Book [AAP 2021]; Stultz 2019; Zhu 2021). Therefore, doxycycline use recommendations cannot be applied to tigecycline. In a dental evaluation of 12 patients who had previously received tigecycline while <8 years old, 2 patients (16.7%) developed mild tooth discoloration after receiving tigecycline for ≥19 days; definitive causation was not able to be assessed (Zhu 2021). In a retrospective chart review of 91 pediatric patients aged 7 months to 17.5 years who received tigecycline for a median of 12 days (range: 3 to 27 days), no tooth discoloration was documented during 2 years of follow-up for any patient; however, study methods limit conclusions (Aslan 2022). Tooth discoloration has been reported in a 9-year-old who received tigecycline for 47 days (Lin 2018).

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution Reconstituted, Intravenous [preservative free]:

Tygacil: 50 mg (1 ea) [contains lactose]

Generic: 50 mg (1 ea)

Generic Equivalent Available: US

Yes

Pricing: US

Solution (reconstituted) (Tigecycline Intravenous)

50 mg (per each): $99.00 - $187.20

Solution (reconstituted) (Tygacil Intravenous)

50 mg (per each): $120.00

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution Reconstituted, Intravenous:

Tygacil: 50 mg (1 ea) [contains lactose]

Generic: 50 mg (1 ea)

Administration: Pediatric

IV: Infuse over 30 to 60 minutes through dedicated line or via Y-site (Ref).

Administration: Adult

IV: Infuse over 30 to 60 minutes through dedicated line or via Y-site. If the same IV line is used for sequential infusion of several drugs, flush line with NS, D5W, or LR before and after tigecycline administration.

Storage/Stability

Store intact vials at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F). Reconstituted solution may be stored at room temperature (not to exceed 25°C [77°F]) for up to 6 hours in the vial or up to 24 hours if further diluted in NS, D5W, or LR. Alternatively, may be stored at 2°C to 8°C (36°F to 46°F) for up to 48 hours following immediate transfer of the reconstituted solution into NS or D5W.

Use

Treatment of complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia caused by susceptible bacteria (FDA approved in ages ≥18 years and adults). Note: Not indicated for the treatment of diabetic foot infections, hospital-acquired pneumonia (HAP), or ventilator-associated pneumonia (VAP); greater mortality and decreased efficacy were reported in tigecycline-treated patients in a comparative clinical trial.

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program

Aminolevulinic Acid (Systemic): Photosensitizing Agents may increase photosensitizing effects of Aminolevulinic Acid (Systemic). Risk X: Avoid

Aminolevulinic Acid (Topical): Photosensitizing Agents may increase photosensitizing effects of Aminolevulinic Acid (Topical). Risk C: Monitor

Bacillus clausii: Antibiotics may decrease therapeutic effects of Bacillus clausii. Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy. Risk D: Consider Therapy Modification

BCG (Intravesical): Antibiotics may decrease therapeutic effects of BCG (Intravesical). Risk X: Avoid

BCG Vaccine (Immunization): Antibiotics may decrease therapeutic effects of BCG Vaccine (Immunization). Risk C: Monitor

Cholera Vaccine: Antibiotics may decrease therapeutic effects of Cholera Vaccine. Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics. Risk X: Avoid

Fecal Microbiota (Live) (Oral): May decrease therapeutic effects of Antibiotics. Risk X: Avoid

Fecal Microbiota (Live) (Rectal): Antibiotics may decrease therapeutic effects of Fecal Microbiota (Live) (Rectal). Risk X: Avoid

Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may decrease therapeutic effects of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). Risk C: Monitor

Lactobacillus and Estriol: Antibiotics may decrease therapeutic effects of Lactobacillus and Estriol. Risk C: Monitor

Lithium: Tetracyclines may increase serum concentration of Lithium. Risk C: Monitor

Mecamylamine: Tetracyclines may increase neuromuscular-blocking effects of Mecamylamine. Risk X: Avoid

Methotrexate: Tetracyclines may increase serum concentration of Methotrexate. Risk C: Monitor

Methoxsalen (Systemic): Photosensitizing Agents may increase photosensitizing effects of Methoxsalen (Systemic). Risk C: Monitor

Methoxyflurane: Tetracyclines may increase nephrotoxic effects of Methoxyflurane. Risk X: Avoid

Mycophenolate: Antibiotics may decrease active metabolite exposure of Mycophenolate. Specifically, concentrations of mycophenolic acid (MPA) may be reduced. Risk C: Monitor

Neuromuscular-Blocking Agents: Tetracyclines may increase neuromuscular-blocking effects of Neuromuscular-Blocking Agents. Risk C: Monitor

Penicillins: Tetracyclines may decrease therapeutic effects of Penicillins. Risk C: Monitor

Porfimer: Photosensitizing Agents may increase photosensitizing effects of Porfimer. Risk X: Avoid

Retinoic Acid Derivatives: Tetracyclines may increase adverse/toxic effects of Retinoic Acid Derivatives. The development of pseudotumor cerebri is of particular concern. Risk X: Avoid

Sodium Bicarbonate (Systemic): May decrease serum concentration of Tetracyclines. Risk C: Monitor

Sodium Picosulfate: Antibiotics may decrease therapeutic effects of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Risk D: Consider Therapy Modification

Sulfonylureas: Tetracyclines may increase hypoglycemic effects of Sulfonylureas. Risk C: Monitor

Tacrolimus (Systemic): Tigecycline may increase serum concentration of Tacrolimus (Systemic). Risk C: Monitor

Typhoid Vaccine: Antibiotics may decrease therapeutic effects of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Avoid use of live attenuated typhoid vaccine (Ty21a) in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose. Risk D: Consider Therapy Modification

Verteporfin: Photosensitizing Agents may increase photosensitizing effects of Verteporfin. Risk C: Monitor

Vitamin K Antagonists: Tetracyclines may increase anticoagulant effects of Vitamin K Antagonists. Risk C: Monitor

Warfarin: Tigecycline may increase serum concentration of Warfarin. Risk C: Monitor

Pregnancy Considerations

Tigecycline crosses the placenta.

Tetracyclines accumulate in developing teeth and long tubular bones (Mylonas 2011). Permanent discoloration of teeth (yellow, gray, brown) can occur following in utero exposure and is more likely to occur following long-term use or short-term repeated exposure. In addition, tetracycline use has been associated with reversible retardation of skeletal development and reduced bone growth.

Monitoring Parameters

Hypersensitivity reactions; hepatic function (baseline and periodic) including bilirubin; coagulation parameters (including aPTT, PTT, and fibrinogen; baseline and regularly during therapy); signs and symptoms of pancreatitis; GI intolerance (eg nausea, vomiting); tooth enamel (pediatric patients <8 years); serum albumin (patients with cystic fibrosis) (CFF/ECFS [Floto 2016]).

Mechanism of Action

A glycylcycline antibiotic that binds to the 30S ribosomal subunit of susceptible bacteria, thereby, inhibiting protein synthesis. Generally considered bacteriostatic; however, bactericidal activity has been demonstrated against isolates of S. pneumoniae and L. pneumophila. Tigecycline is a derivative of minocycline (9-t-butylglycylamido minocycline), and while not classified as a tetracycline, it may share some class-associated adverse effects. Tigecycline has demonstrated activity against a variety of gram-positive and -negative bacterial pathogens including methicillin-resistant staphylococci.

Pharmacokinetics (Adult Data Unless Noted)

Distribution: Vd:

Children 8 to 11 years: 2.84 L/kg (range: 0.397 to 11.2 L/kg) (Purdy 2012).

Adults: 7 to 9 L/kg; extensive tissue distribution; distributes into gallbladder, lung, and colon.

Protein binding: 71% to 89%.

Metabolism: Hepatic, via glucuronidation, N-acetylation, and epimerization to several metabolites, each <10% of the dose.

Half-life elimination: Single dose: 27 hours; following multiple doses: 42 hours; increased by 23% in moderate hepatic impairment and 43% in severe hepatic impairment.

Excretion: Feces (59%, primarily as unchanged drug); urine (33%, with 22% of the total dose as unchanged drug).

Clearance: Reduced by 25% in patient with moderate hepatic impairment and 55% in severe hepatic impairment.

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Anti-infective considerations:

Parameters associated with efficacy: AUC24/minimum inhibitory concentration (MIC) or free AUC/MIC (fAUC24/MIC) (Barbour 2009; Bhavnani 2010; Bhavnani 2012; Meagher 2007; Passarell 2008). Reported AUC/MIC or fAUC/MIC targets variable; may depend on specific pathogen and inoculum, site of infection, and other host factors (Crandon 2009; Tsala 2017).

Pathogen-specific targets:

A. baumannii: fAUC/MIC: ≥17 (80% efficacy); ≥8 (50% efficacy); ≥6 (stasis) (Koomanachai 2009a).

E. coli: fAUC/MIC: ≥8 (2 log10 reduction); ≥2 (stasis) (Zhanel 2009).

K. pneumoniae (carbapenemase-producing): fAUC/MIC: ≥16 (103 inocula; increases with increasing inocula) (Tsala 2017).

S. aureus: fAUC/MIC: ≥3 to 5.4 (Crandon 2009; Koomanachai 2009b).

Expected drug exposure in normal kidney function:

AUC0-24 (total): IV, steady state:

Children 8 to 11 years of age: 1.25 mg/kg/dose every 12 hours; maximum dose: 50 mg/dose (30-minute infusion): 6.392 ± 3.408 mg•hour/L (Purdy 2012).

Adults: 100 mg loading dose, followed by 50 mg every 12 hours: Mean range: ~3.5 to 5.4 mg•hour/L (Conte 2005; Meagher 2007; Sun 2005; manufacturer's labeling).

Postantibiotic effect: Bacterial growth suppression continues after tigecycline concentration falls below the MIC of targeted pathogen and varies based on the organism. The postantibiotic effect for tigecycline typically ranges between ~1 and 6 hours (Lefort 2003; Pankuch 2009).

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Tygacil;
  • (AR) Argentina: Tizoxim | Tygacil;
  • (AT) Austria: Tigecyclin mylan | Tigecyclin sandoz;
  • (BD) Bangladesh: Tigacil | Widebac;
  • (BE) Belgium: Tigecyclin sandoz | Tigecycline accord | Tygacil;
  • (BG) Bulgaria: Tigecycline accord | Tigecycline sandoz | Tygacil;
  • (BR) Brazil: Kalyme | Tigeciclina | Tygacil | Tyzel;
  • (CL) Chile: Tigeciclina | Tigevitae | Tygacil;
  • (CN) China: Ao ti jia;
  • (CO) Colombia: Expociclina | Geclix | Linicetil | Tigecic | Tigeciclina | Tigevitae | Tiglex | Tygacil;
  • (CZ) Czech Republic: Tigecycline accord | Tigecycline mylan | Tigecycline olikla | Tigecycline sandoz | Tigecycline teva | Tygacil;
  • (DE) Germany: Tigecyclin hexal | Tigecyclin mylan | Tigecyclin ratiopharm;
  • (DO) Dominican Republic: Tygacil;
  • (EC) Ecuador: Tigeciclina | Tygacil | Tygelina;
  • (EE) Estonia: Tigecycline accord | Tygacil;
  • (EG) Egypt: Tegasterk | Tygacil;
  • (ES) Spain: Tigeciclina accord | Tigeciclina mylan | Tigeciclina normon;
  • (FI) Finland: Tigecycline accord | Tygacil;
  • (FR) France: Tigecycline mylan | Tygacil;
  • (GB) United Kingdom: Tygacil;
  • (GR) Greece: Digazor | Tygacil;
  • (HK) Hong Kong: Tigevitae | Tygacil;
  • (HU) Hungary: Tigecycline teva;
  • (IE) Ireland: Tigecycline accord | Tygacil;
  • (IN) India: Algeline | Cachtin | Critig | Emtig | Het tg | Innocycline | Tigaphar | Tigebax | Tigecross | Tigene | Tigeniche | Tigeo | Tigerad | Tigercin | Tigeshan | Tigetuf | Tigi | Tigitrust | Tiziren | Tygacil | Tygaray | Zutig;
  • (IT) Italy: Tigeciclina | Tigeciclina mylan pharma;
  • (JO) Jordan: Tagix | Tygacil;
  • (JP) Japan: Tygacil;
  • (KE) Kenya: Tigebax | Tygacil | Tylin;
  • (KR) Korea, Republic of: Penmix tigecycline | Tygacil;
  • (KW) Kuwait: Tygacil;
  • (LB) Lebanon: Tagix | Tygacil;
  • (LT) Lithuania: Tygacil;
  • (LV) Latvia: Tigecycline accord | Tygacil;
  • (MX) Mexico: Gecifhil | Grexyl | Linicetil | Treprex | Tygacil;
  • (MY) Malaysia: Tigar | Tygacil | Tylin;
  • (NG) Nigeria: Tygacil;
  • (NL) Netherlands: Tygacil;
  • (NZ) New Zealand: Tigecycline juno | Tygacil;
  • (PE) Peru: Tigevitae | Tigilyn | Zomiprerin pd;
  • (PK) Pakistan: Tagagy | Tegecin | Tigacel | Tigasafe | Tigcil | Tigelin | Tigemark | Tigewel | Tigowin | Tilane | Tygacil | Tygin;
  • (PL) Poland: Tigecycline accord | Tigecycline mylan | Tigecycline sandoz;
  • (PT) Portugal: Tigeciclina accord | Tigeciclina mylan | Tigeciclina tecnigen | Tigeciclina teva | Tygacil;
  • (PY) Paraguay: Spemicina | Tigeciclina cellofarm | Tigeciclina dasanti | Tigeciclina demotek | Tigeciclina imedic | Tygacil;
  • (QA) Qatar: Tygacil;
  • (RO) Romania: Tigeciclina atb | Tigeciclina mylan | Tigeciclina rompharm | Tygacil;
  • (RU) Russian Federation: Tigacil | Tigecycline j | Tigecycline psk;
  • (SA) Saudi Arabia: Tygacil;
  • (SE) Sweden: Tigecycline accord | Tigecycline eql pharma | Tigecycline mylan | Tygacil;
  • (SI) Slovenia: Tigeciklin accord | Tigeciklin sandoz | Tygacil;
  • (SK) Slovakia: Tigecycline accord | Tigecycline sandoz | Tygacil;
  • (TH) Thailand: Bacticil | Capessa | Tigeline | Tyzel;
  • (TN) Tunisia: Tygacil;
  • (TR) Turkey: Mrsacin | Tigecid | Tigeject | Tigenex | Tigesil liyo | Tybicid | Tygepol | Tygex;
  • (TW) Taiwan: Tigelin | Tygacil;
  • (UA) Ukraine: Tigecycline vista;
  • (UY) Uruguay: Tygacil | Tygelina;
  • (VE) Venezuela, Bolivarian Republic of: Tigemed;
  • (ZA) South Africa: Rubicil | Tacyl | Tigebax | Tigecycline accord | Tygacil
  1. American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. Red Book: 2021 Report of the Committee on Infectious Diseases. 32nd ed. American Academy of Pediatrics; 2021.
  2. Aslan K, Kiliç Ö, Kiral E, Bozan G, Bör Ö, Dinleyici EÇ. Clinical and laboratory responses to tigecycline in children. J Clin Pharm Ther. 2022;47(10):1585-1590. doi:10.1111/jcpt.13708 [PubMed 36196509]
  3. Barbour A, Schmidt S, Ma B, et al. Clinical pharmacokinetics and pharmacodynamics of tigecycline. Clin Pharmacokinet. 2009;48(9):575-584. doi:10.2165/11317100-000000000-00000 [PubMed 19725592]
  4. Bergallo C, Jasovich A, Teglia O, et al, “Safety and Efficacy of Intravenous Tigecycline in Treatment of Community-Acquired Pneumonia: Results From a Double-Blind Randomized Phase 3 Comparison Study With Levofloxacin,” Diagn Microbiol Infect Dis, 2009, 63(1):52-61. [PubMed 18990531]
  5. Bhavnani SM, Rubino CM, Ambrose PG, Babinchak TJ, Korth-Bradley JM, Drusano GL. Impact of different factors on the probability of clinical response in tigecycline-treated patients with intra-abdominal infections. Antimicrob Agents Chemother. 2010;54(3):1207-1212. doi:10.1128/AAC.00182-09 [PubMed 20038623]
  6. Bhavnani SM, Rubino CM, Hammel JP, et al. Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. Antimicrob Agents Chemother. 2012;56(2):1065-1072. doi:10.1128/AAC.01615-10 [PubMed 22143524]
  7. Broeker A, Wicha SG, Dorn C, et al. Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study. Crit Care. 2018;22(1):341. doi:10.1186/s13054-018-2278-4 [PubMed 30558639]
  8. Chen F, Shen C, Pang X, et al. Effectiveness of tigecycline in the treatment of infections caused by carbapenem-resistant gram-negative bacteria in pediatric liver transplant recipients: a retrospective study. Transpl Infect Dis. 2020;22(1):e13199. doi:10.1111/tid.13199 [PubMed 31627248]
  9. Chen Z, Shi X. Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens. Medicine (Baltimore). 2018;97(38):e12467. doi:10.1097/MD.0000000000012467 [PubMed 30235740]
  10. Chiotos K, Hayes M, Gerber JS, Tamma PD. Treatment of carbapenem-resistant Enterobacteriaceae infections in children. J Pediatric Infect Dis Soc. 2020;9(1):56-66. doi:10.1093/jpids/piz085 [PubMed 31872226]
  11. Conte JE Jr, Golden JA, Kelly MG, Zurlinden E. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents. 2005;25(6):523-529. doi:10.1016/j.ijantimicag.2005.02.013 [PubMed 15885987]
  12. Crandon JL, Banevicius MA, Nicolau DP. Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model. Antimicrob Agents Chemother. 2009;53(3):1165-1169. doi:10.1128/AAC.00647-08 [PubMed 19114676]
  13. Cui N, Cai H, Li Z, Lu Y, Wang G, Lu A. Tigecycline-induced coagulopathy: a literature review. Int J Clin Pharm. 2019;41(6):1408‐1413. doi:10.1007/s11096-019-00912-5 [PubMed 31713108]
  14. Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Clin Infect Dis. 2020;71(4):905-913. doi:10.1093/cid/ciaa1125 [PubMed 32797222]
  15. Dartois N, Castaing N, Gandjini H, et al, “Tigecycline Versus Levofloxacin for the Treatment of Community-Acquired Pneumonia: European Experience,” J Chemother, 2008, 20(Suppl 1):28-35. [PubMed 19036672]
  16. De Pascale G, Montini L, Pennisi M, et al. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit Care. 2014;18(3):R90. doi:10.1186/cc13858 [PubMed 24887101]
  17. Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.; id: Expert.DOR
  18. File TM. Treatment of community-acquired pneumonia in adults who require hospitalization. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 13, 2021.
  19. Floto RA, Olivier KN, Saiman L, et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax. 2016;71(suppl 1):i1–i22. doi:10.1136/thoraxjnl-2015-207360 [PubMed 26666259]
  20. Freire AT, Melnyk V, Kim MJ, et al; 311 Study Group. Comparison of tigecycline with imipenem/ cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis. 2010;68(2):140-151. [PubMed 2084658]
  21. Fritsche TR and Jones RN, "Antimicrobial Activity of Tigecycline (GAR-936) Tested Against 3498 Recent Isolates of Staphylococcus aureus Recovered From Nosocomial and Community-Acquired Infections," Int J Antimicrob Agents, 2004, 24(6):567-71. [PubMed 15555879]
  22. Gomi H, Solomkin JS, Schlossberg D, et al. Tokyo guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci. 2018;25(1):3-16. doi:10.1002/jhbp.518 [PubMed 29090866]
  23. Haworth CS, Banks J, Capstick T, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax. 2017;72(suppl 2):ii1‐ii64. doi:10.1136/thoraxjnl-2017-210927 [PubMed 29054853]
  24. Iosifidis E, Violaki A, Michalopoulou E, et al. Use of tigecycline in pediatric patients with infections predominantly due to extensively drug-resistant gram-negative bacteria. J Pediatric Infect Dis Soc. 2017;6(2):123-128. doi:10.1093/jpids/piw009 [PubMed 27000866]
  25. Jacobus NV, McDermott LA, Ruthazer R, et al, "In Vitro Activities of Tigecycline Against the Bacteroides fragilis Group," Antimicrob Agents Chemother, 2004, 48(3):1034-6. [PubMed 14982803]
  26. Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61-e111. [PubMed 27418577]
  27. Kim SR, Jang M, Kim SY, Kim DH, Jhun BW. Outcomes of short-term tigecycline-containing regimens for mycobacterium abscessus pulmonary disease. Antimicrob Agents Chemother. 2022;66(10):e0077422. doi:10.1128/aac.00774-22 [PubMed 36165626]
  28. Koomanachai P, Crandon JL, Banevicius MA, Peng L, Nicolau DP. Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model. Antimicrob Agents Chemother. 2009b;53(12):5060-5063. doi:10.1128/AAC.00985-09 [PubMed 19738006]
  29. Koomanachai P, Kim A, Nicolau DP. Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model. J Antimicrob Chemother. 2009a;63(5):982-987. doi:10.1093/jac/dkp056 [PubMed 19279050]
  30. Korth-Bradley JM, Troy SM, Matschke K, Muralidharan G, Fruncillo RJ, Speth JL, Raible DG. Tigecycline pharmacokinetics in subjects with various degrees of renal function. J Clin Pharmacol. 2012;52(9):1379-1387. doi:10.1177/0091270011416938 [PubMed 21953572]
  31. Lefort A, Lafaurie M, Massias L, et al. Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis. Antimicrob Agents Chemother. 2003;47(1):216-222. doi:10.1128/AAC.47.1.216-222.2003 [PubMed 12499194]
  32. Lin S, Liang L, Zhang C, Ye S. Preliminary experience of tigecycline treatment in critically ill children with ventilator-associated pneumonia. J Int Med Res. 2020;48(1):300060518760435. doi:10.1177/0300060518760435 [PubMed 29614915]
  33. Lin S, Zhang C, Ye S. Preliminary experience of tigecycline treatment for infection in children with hematologic malignancies. Int J Clin Pharm. 2018;40(5):1030-1036. doi: 10.1007/s11096-018-0690-0 [PubMed 30051224]
  34. Lipsky BA, Berendt AR, Cornia PB, et al. 2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections. Clin Infect Dis. 2012;54(12):e132-e173. [PubMed 22619242]
  35. Longworth SA, Daly JS; AST Infectious Diseases Community of Practice. Management of infections due to nontuberculous mycobacteria in solid organ transplant recipients -Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13588. doi: 10.1111/ctr.13588 [PubMed 31077618]
  36. Mazuski JE, Tessier JM, May AK, et al. The Surgical Infection Society revised guidelines on the management of intra-abdominal infection. Surg Infect (Larchmt). 2017;18(1):1-76. doi:10.1089/sur.2016.261 [PubMed 28085573]
  37. Meagher AK, Passarell JA, Cirincione BB, et al. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob Agents Chemother. 2007;51(6):1939-1945. doi:10.1128/AAC.01084-06 [PubMed 17353238]
  38. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST [PubMed 31573350]
  39. Munoz-Price LS and Weinstein RA, “Acinetobacter Infection,” N Engl J Med, 2008, 358(12):1271-81. [PubMed 18354105]
  40. Muralidharan G, Micalizzi M, Speth J, et al, "Pharmacokinetics of Tigecycline After Single and Multiple Doses in Healthy Subjects," Antimicrob Agents Chemother, 2005, 49(1):220-9. [PubMed 15616299]
  41. Mylonas I. Antibiotic chemotherapy during pregnancy and lactation period: aspects for consideration. Arch Gynecol Obstet. 2011;283(1):7-18. doi: 10.1007/s00404-010-1646-3. [PubMed 20814687]
  42. Pankuch GA, Appelbaum PC. Postantibiotic effect of tigecycline against 14 gram-positive organisms. Antimicrob Agents Chemother. 2009;53(2):782-784. doi:10.1128/AAC.01122-08 [PubMed 19064899]
  43. Passarell JA, Meagher AK, Liolios K, et al. Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections. Antimicrob Agents Chemother. 2008;52(1):204-210. doi:10.1128/AAC.00813-07 [PubMed 17954694]
  44. Peleg AY, Potoski BA, Rea R, et al, “Acinetobacter baumannii Bloodstream Infection While Receiving Tigecycline: A Cautionary Report,” J Antimicrobic Chemother, 2007, 59(1):128-31. [PubMed 17082201]
  45. Purdy J, Jouve S, Yan JL, et al. Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. Clinical Therapeutics. 2012;34(2): 496-507. doi:10.1016/j.clinthera.2011.12.010 [PubMed 22249106]
  46. Ramirez J, Dartois N, Gandjini H, Yan JL, Korth-Bradley J, McGovern PC. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother. 2013;57(4):1756-1762. [PubMed 23357775]
  47. Refer to manufacturer's labeling.
  48. Rose WE and Rybak MJ, “Tigecycline: First of a New Class of Antimicrobial Agents,” Pharmacotherapy, 2006, 26(8):1099–110. [PubMed 16863487]
  49. Sawyer RG, Claridge JA, Nathens AB, et al; STOP-IT Trial Investigators. Trial of short-course antimicrobial therapy for intraabdominal infection. N Engl J Med. 2015;372(21):1996-2005. doi:10.1056/NEJMoa1411162 [PubMed 25992746]
  50. Shulha JA, Escalante P, Wilson JW. Pharmacotherapy approaches in nontuberculous mycobacteria infections. Mayo Clin Proc. 2019;94(8):1567-1581. doi: 10.1016/j.mayocp.2018.12.011 [PubMed 31160063]
  51. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infections in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(2):133-164. [PubMed 20034345]
  52. Song Y, Hu L, Shu Q, et al. Tigecycline salvage therapy for critically ill children with multidrug-resistant/extensively drug-resistant infections after surgery. Int J Infect Dis. 2018;75:82-88. doi:10.1016/j.ijid.2018.08.007 [PubMed 30125690]
  53. Stultz JS, Eiland LS. Doxycycline and tooth discoloration in children: changing of recommendations based on evidence of safety. Ann Pharmacother. 2019;53(11):1162-1166. doi:10.1177/1060028019863796 [PubMed 31280586]
  54. Sun HK, Ong CT, Umer A, et al. Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Antimicrob Agents Chemother. 2005;49(4):1629-1632. doi:10.1128/AAC.49.4.1629-1632.2005 [PubMed 15793157]
  55. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections. Clin Infect Dis. Published online July 18, 2023. doi:10.1093/cid/ciad428 [PubMed 37463564]
  56. Tanaseanu C, Bergallo C, Teglia O, et al, “Integrated Results of 2 Phase 3 Studies Comparing Tigecycline and Levofloxacin in Community-Acquired Pneumonia,” Diagn Microbiol Infect Dis, 2008, 61(3):329-38. [PubMed 18508226]
  57. Tanaseanu C, Milutinovic S, Calistru PI, et al; 313 Study Group. Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia. BMC Pulm Med. 2009;9:44. doi:10.1186/1471-2466-9-44 [PubMed 19740418]
  58. Tsala M, Vourli S, Daikos GL, et al. Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae. J Antimicrob Chemother. 2017;72(1):172-180. doi:10.1093/jac/dkw354 [PubMed 27650184]
  59. Tygacil (tigecycline) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc; March 2025.
  60. Tygacil (tigecycline) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; August 2021.
  61. Tygacil (tigecycline) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; July 2023.
  62. Tygacil (tigecycline) [summary of product characteristics]. Bruxelles, Belgium: Pfizer Europe MA EEIG; February 2016.
  63. US Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new Boxed Warning. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-increased-risk-death-iv-antibacterial-tygacil-tigecycline. Published September 27, 2013. Accessed September 14, 2021.
  64. Wallace RJ Jr, Dukart G, Brown-Elliott BA, Griffith DE, Scerpella EG, Marshall B. Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infections. J Antimicrob Chemother. 2014;69(7):1945-1953. doi:10.1093/jac/dku062 [PubMed 24633206]
  65. World Health Organization (WHO); UNICEF. Breastfeeding and maternal medication: recommendations for drugs in the eleventh WHO model list of essential drugs. http://www.who.int/maternal_child_adolescent/documents/55732/en. Published 2002.
  66. Yang JH, Wang PH, Pan SW, et al. Treatment outcome in patients with mycobacterium abscessus complex lung disease: the impact of tigecycline and amikacin. Antibiotics (Basel). 2022;11(5):571. doi:10.3390/antibiotics11050571 [PubMed 35625215]
  67. Ye S, Zhang C, Lin S. Preliminary experience with tigecycline treatment for severe infection in children. Eur J Pediatr. 2018;177(10):1489-1496. doi: 10.1007/s00431-018-3208-9 [PubMed 30008076]
  68. Zeng J, Zhang L, Gao M, et al. Tigecycline treatment in an infant with extensively drug-resistant Acinetobacter baumannii bacteremia. Int J Infect Dis. 2017;61:23-26. [PubMed 28572073]
  69. Zha L, Pan L, Guo J, French N, Villanueva EV, Tefsen B. Effectiveness and safety of high dose tigecycline for the treatment of severe infections: a systematic review and meta-analysis. Adv Ther. 2020;37(3):1049-1064. doi:10.1007/s12325-020-01235-y [PubMed 32006240]
  70. Zhanel GG, Baudry PJ, Tailor F, Cox L, Hoban DJ, Karlowsky JA. Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model. J Antimicrob Chemother. 2009;64(4):824-828. doi:10.1093/jac/dkp254 [PubMed 19643776]
  71. Zhanel GG, Homenuik K, Nichol K, et al, "The Glycylcyclines: A Comparative Review With the Tetracyclines," Drugs, 2004, 64(1):63-88. [PubMed 14723559]
  72. Zhu Z, Yu Q, Qi G, et al. Tigecycline-induced tooth discoloration in children younger than eight tears. Antimicrob Agents Chemother. 2021;65(9):e0085421. doi: 10.1128/AAC.00854-21 [PubMed 34228549]
  73. Zhu ZY, Yang JF, Ni YH, Ye WF, Wang J, Wu ML. Retrospective analysis of tigecycline shows that it may be an option for children with severe infections. Acta Paediatr. 2016;105(10):e480-484. [PubMed 27381360]
Topic 13076 Version 236.0